Circutrol BP
90/100
This product looks safe
- Contains proprietary blend — exact ingredient amounts not disclosed
- 67% of ingredients have research evidence
A
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Safety Alerts
ℹ️ Contains proprietary blend — exact ingredient amounts not disclosed
Label Data
2 Capsule(s)
Serving Size
30
Servings
Botanical with Nutrients
Product Type
67%
Evidence Coverage
Supplement Facts — Evidence Check
45 mcg
(56% DV)
✅ Within RDA (0.4× RDA of 0.12 mg)
📚 273 studies (Tier A: 9, B: 175)
150 mg
📊 Market median: 100.0mg (284 products)
📚 10 studies (Tier A: 0, B: 4)
Proprietary Blend
330 mg
Other Ingredients
Microcrystalline Cellulose
Hydroxypropylmethylcellulose
Magnesium Stearate
Silicon Dioxide
Label Claims — Verification
❓
Nutrient
❓
All Other
All Other (100% of products)
Structure/Function (84% of products)
Nutrient (73% of products)
Target Groups
Adult (18 - 50 Years)
Product Information
📋 Directions for Use
Directions: Take two capsules per day.
⚠️ Warnings & Precautions
Keep out of reach of children.
🧪 Formulation Notes
Description: This formula contains targeted nutrients for maintaining optimal blood pressure and cardiovascular health - vitamin k2 and grape seed extract. Plus you get researched levels of new green coffee bean extract and beneficial amounts of pomegranate extract for superior antioxidant protection of your arterial walls for peak flexibility.
Additional Information
TESTED FOR QUALITY & PURITY
Code Number: 3610
M MegaNatural BP
Since 1979
VRP
This product is manufactured in accordance with current Good Manufacturing Practices (GMP).
0430
300-VRP3610-C
Product Details
UPC / SKU
8 10832 01360 0
DSLD Entry Date
2014-06-25
Product Type
Botanical with Nutrients
Form
Capsule
DSLD ID
33977
Data Updated
2026-04-11
Research Evidence
332
Research Sources
59
Avg Quality Score
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
A
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
A
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
A
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
A
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
A
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
A
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
A
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Compare Similar Products
Vitamin D Synergy with Vitamin K1
Designs for Health
100
Vitamin D Synergy with Vitamin K1
Designs for Health
100
Natural Vitamin K2 45 mcg
Doctor's Best
100
K 100 mcg
Thompson
100
Vitamin K2 300 mcg MK-7
Innerzyme
100